354 related articles for article (PubMed ID: 35738640)
1. Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.
Mima A; Horii Y
In Vivo; 2022; 36(4):1785-1789. PubMed ID: 35738640
[TBL] [Abstract][Full Text] [Related]
2. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
Akizawa T; Ueno M; Shiga T; Reusch M
Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
[TBL] [Abstract][Full Text] [Related]
3. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
[TBL] [Abstract][Full Text] [Related]
4. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
Fishbane S; El-Shahawy MA; Pecoits-Filho R; Van BP; Houser MT; Frison L; Little DJ; Guzman NJ; Pergola PE
J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
[TBL] [Abstract][Full Text] [Related]
5. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
[TBL] [Abstract][Full Text] [Related]
6. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
Fishbane S; Pollock CA; El-Shahawy M; Escudero ET; Rastogi A; Van BP; Frison L; Houser M; Pola M; Little DJ; Guzman N; Pergola PE
J Am Soc Nephrol; 2022 Apr; 33(4):850-866. PubMed ID: 35361724
[TBL] [Abstract][Full Text] [Related]
7. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089
[TBL] [Abstract][Full Text] [Related]
8. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
Provenzano R; Besarab A; Sun CH; Diamond SA; Durham JH; Cangiano JL; Aiello JR; Novak JE; Lee T; Leong R; Roberts BK; Saikali KG; Hemmerich S; Szczech LA; Yu KP; Neff TB
Clin J Am Soc Nephrol; 2016 Jun; 11(6):982-991. PubMed ID: 27094610
[TBL] [Abstract][Full Text] [Related]
9. Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin.
Yang X; Zhao B; Wang J; Wang L; Tao M; Lu J; Lin J; Sun J; Wang R
Ren Fail; 2021 Dec; 43(1):1428-1436. PubMed ID: 34657570
[TBL] [Abstract][Full Text] [Related]
10. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
[TBL] [Abstract][Full Text] [Related]
11. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
12. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
[TBL] [Abstract][Full Text] [Related]
13. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
Akizawa T; Yamaguchi Y; Majikawa Y; Reusch M
Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
[TBL] [Abstract][Full Text] [Related]
15. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
Doggrell SA
Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness.
Liu J; Li S; Yang F; Li T; Li R; Waheed Y; Meng C; Li S; Liu K; Tong Y; Xu H; Tian C; Zhou X
Korean J Intern Med; 2024 May; 39(3):488-500. PubMed ID: 38649158
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
18. Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients.
Song J; Chen X; Zhou L; Yu W; Liu H; Yuan F
J Int Med Res; 2023 Oct; 51(10):3000605231204475. PubMed ID: 37843847
[TBL] [Abstract][Full Text] [Related]
19. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
20. A phase 3b, multicenter, open-label, single-arm study of roxadustat within a US dialysis organization: The DENALI study.
Larkin J; Hymes J; Britton ML; Oluwatosin Y; Nolen J; Zhu L; Silva A
Hemodial Int; 2024 Jan; 28(1):59-71. PubMed ID: 37875459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
